Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because
clinical symptoms are strongly correlated with tau aggregates, drug development and …

Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …

A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …

Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …

Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …